Virtu Financial LLC Grows Holdings in Stryker Corporation $SYK

Virtu Financial LLC raised its position in Stryker Corporation (NYSE:SYK) by 150.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,895 shares of the medical technology company’s stock after buying an additional 2,943 shares during the period. Virtu Financial LLC’s holdings in Stryker were worth $1,720,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares in the last quarter. State Street Corp grew its stake in Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC increased its holdings in Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. JPMorgan Chase & Co. cut their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Evercore set a $355.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Trading Up 0.3%

Shares of NYSE SYK opened at $308.62 on Friday. The company has a market cap of $118.31 billion, a price-to-earnings ratio of 35.72, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $313.81 and its 200 day simple moving average is $341.71.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.